On Aug. 29, Medicare released its highly anticipated list of 10 therapies for which it plans to establish a price by 2026. The Inflation Reduction
Looking at the dizzying progress in cancer medicine over the last couple of decades, it’s easy to imagine that advances in synthetic biology or immunology
WASHINGTON — Republicans on three key House committees have reconciled their differing legislative packages to increase transparency in the health care system and reform payment
More older adults have been hospitalized for Covid-19 over the past several weeks, according to internal data reviewed by health insurance giant Humana. Humana, which
WASHINGTON — Astellas was so sure that one of its drugs was going to be selected as part of Medicare’s new drug price negotiation program
In this new podcast, Bruker’s Kate Stumpo talks with Enveda’s Pelle Simpson on the opportunities of natural products in the field of multiomics.
If you’ve been following the psychedelics renaissance unfolding over the last two decades, you probably have heard of Dr. Matthew Johnson, a professor of psychiatry
AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder Awakn Life Sciences Corp. (NEO:
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class